Opinion|Videos|April 18, 2025
Population Outcomes and Return on Value With CGMs
Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What metrics do you use to evaluate CGM's comprehensive return on investment, including both cost savings and quality measure performance?
- Which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, and how do you prioritize these groups for CGM access?
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.
Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Youths with depression had about twice the odds of prescription drug misuse and 4 times the odds of use disorder, compared with peers without depression.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Experts Pitch National Risk Pool to Fund Gene Therapy Access
5